Shawn Singh, VistaGen CEO (Jason Koerner/Getty Images for Concordia Summit)
VistaGen faces another fail as anxiety drug flops a PhIII study — shares crater
VistaGen Therapeutics’ social anxiety drug flopped in a Phase III trial, the company announced Friday, adding to its list of programs that haven’t panned out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.